---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-019075"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:43:22.514698+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences Q1 net loss $30.6M; cash $191M funds into 2024

## Summary
- Net loss $30.6M in Q1 2022 vs. $11.7M in Q1 2021; R&D spend $25.5M (up from $8.2M).
- Cash & equivalents $191.0M as of March 31, 2022, compared to $219.7M at year-end 2021.
- Initial APEX Phase 2 data for bezuclastinib in AdvSM to be presented at EHA June 2022.
- FGFR2 inhibitor advancing toward IND in H2 2023; ErbB2 mutant selective program announced.
- SUMMIT (NonAdvSM) and PEAK (GIST) trials actively enrolling patients.

## SEC filing metadata
- accession: 0001564590-22-019075
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000156459022019075/0001564590-22-019075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000156459022019075/cogt-8k_20220510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-019075
- JSON: https://secwatch.observer/filing/0001564590-22-019075.json
- Plain text: https://secwatch.observer/filing/0001564590-22-019075.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.